PUBLISHER: The Business Research Company | PRODUCT CODE: 1426330
PUBLISHER: The Business Research Company | PRODUCT CODE: 1426330
Transthyretin amyloidosis is a gradually progressing condition marked by the accumulation of abnormal protein deposits in the body's organs and tissues. Treatment for transthyretin amyloidosis involves various medical interventions and therapeutic strategies aimed at managing and alleviating the impacts of this condition.
The primary categories of transthyretin amyloidosis treatment include transthyretin amyloidosis with polyneuropathy (ATTR-PN) and transthyretin amyloidosis with cardiomyopathy (ATTR-CM). ATTR-PN involves the abnormal deposition of transthyretin protein in nerves, resulting in peripheral neuropathy and other neurological symptoms. Treatment options for these conditions include drugs such as tafamidis, patisiran, inotersen, as well as targeted therapy, supportive therapy, and pipeline therapies. These treatments are made available through various distribution channels, including hospital pharmacies, specialty pharmacies, retail pharmacies, and online pharmacies.
The transthyretin amyloidosis treatment market research report is one of a series of new reports from The Business Research Company that provides transthyretin amyloidosis treatment market statistics, including transthyretin amyloidosis treatment industry global market size, regional shares, competitors with a transthyretin amyloidosis treatment market share, detailed transthyretin amyloidosis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the transthyretin amyloidosis treatment industry. This transthyretin amyloidosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future- scenario of the industry.
The transthyretin amyloidosis treatment market size has grown strongly in recent years. It will grow from $5.07 billion in 2023 to $5.52 billion in 2024 at a compound annual growth rate (CAGR) of 8.9%. The growth observed in the historic period can be attributed to heightened awareness of the disease, advancements in diagnostic tools, developments and approvals in drug therapies, increased support from patient advocacy groups, and collaborative efforts in research initiatives.
The transthyretin amyloidosis treatment market size is expected to see strong growth in the next few years. It will grow to $7.42 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%. The anticipated growth in the forecast period can be attributed to the expansion of therapeutic pipelines, the rise in genetic screening, global initiatives to raise awareness of rare diseases, the adoption of personalized medicine approaches, and improved access to treatment. Major trends expected in the forecast period include the emergence of combination therapies, strategic partnerships for drug development, a focus on targeting peripheral and cardiac manifestations, the implementation of patient education programs, and the incorporation of real-world evidence in treatment guidelines.
Increased investments in research and development (R&D) are projected to be the driving force behind the growth of the transthyretin amyloidosis treatment market. R&D investments encompass financial resources allocated towards advancing scientific knowledge, developing new technologies, creating innovative products, and enhancing existing processes. Augmented funding in R&D endeavors facilitates the discovery and advancement of novel treatment methodologies for transthyretin amyloidosis. These approaches include pioneering drugs, gene therapies, and precision medicine techniques, which offer patients more effective and targeted treatment options. For instance, Alnylam Pharmaceuticals, a US-based biopharmaceutical company, elevated its research and development investment from $792,156 in 2021 to $883,015 in 2022, indicating an 11.49% growth. Thus, the escalating investment in research and development is anticipated to propel the growth of the transthyretin amyloidosis treatment market.
The expanding demographic of the aging population is poised to be a significant driver of growth in the transthyretin amyloidosis treatment market. An aging population signifies a demographic shift characterized by an increased median age due to declining fertility rates and longer life expectancies. Age is a substantial risk factor for transthyretin amyloidosis (ATTR), and as the population ages, the prevalence of cases pertaining to this condition rises. Consequently, there is a growing pool of patients necessitating treatment. For example, according to the World Health Organization's October 2022 report, every country globally is witnessing an upsurge in both the quantity and proportion of older individuals in the population. By 2030, it's projected that 1 in 6 people worldwide will be aged 60 years or older. Hence, the burgeoning demographics of the aging population are steering the growth of the transthyretin amyloidosis treatment market.
The substantial cost associated with treatment poses a potential barrier to accessing care and might impede the growth of the transthyretin amyloidosis treatment market in the foreseeable period. High treatment costs can hinder patient access, particularly for individuals affected by transthyretin amyloidosis lacking sufficient insurance coverage. This situation often leads to delayed diagnosis and treatment, exacerbating the disease and heightening the risk of complications. For instance, data from the Journal of the American College of Cardiology in February 2021 revealed that Tafamidis, a medication utilized in transthyretin amyloid cardiomyopathy treatment, was priced at $225,000 annually. Consequently, the steep treatment expenses act as a hindrance to the growth of the transthyretin amyloidosis treatment market.
Leading companies within the transthyretin amyloidosis treatment sector are prioritizing the development of innovative and specialized therapies, notably orphan drugs, aiming to improve patient outcomes and broaden treatment options. Orphan drugs such as Eplontersen are specifically tailored to address transthyretin amyloidosis, often receiving regulatory advantages to facilitate their development. For instance, Ionis Pharmaceuticals, Inc., a Canada-based biotechnology research company, obtained Food and Drug Administration (FDA) approval for a new drug application concerning Eplontersen in March 2023. Eplontersen, an experimental orphan drug, is intended for the treatment of familial transthyretin-mediated amyloid, which leads to progressive polyneuropathy. Functioning as a pharmaceutical agent, Eplontersen is designed to decrease transthyretin (TTR) protein synthesis, targeting both hereditary and non-hereditary variations of ATTR amyloidosis (amyloid transthyretin amyloidosis). The FDA had granted Eplontersen orphan drug designation in 2022.
In July 2021, Novo Nordisk AS, a Denmark-based pharmaceutical manufacturer, completed the acquisition of Prothena Corporation PLC's ATTR Amyloidosis Program for $1.2 billion. Through this strategic purchase, Novo Nordisk gained access to Prothena's clinical-stage antibody PRX004 and its comprehensive initiative aimed at treating ATTR amyloidosis. PRX004 represents an anti-amyloid immunotherapeutic in the phase 2 developmental stage, specifically designed to target and remove amyloid accumulations closely associated with the pathological symptoms of ATTR amyloidosis. Prothena Corporation PLC is an Ireland-based biotechnology company recognized for its expertise in the discovery and development of innovative therapies tailored for transthyretin amyloidosis.
Major companies operating in the transthyretin amyloidosis treatment market report are Pfizer Inc, Abbvie Inc, Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca plc, GSK Plc, Novo Nordisk A/S, Merck & Co. Inc, Astellas Pharma Inc., Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc, PTC Therapeutics, Ionis Pharmaceuticals, Prothena Corporation plc, BridgeBio Pharma Inc., Sorrento Therapeutics Inc., Intellia Therapeutics, Akcea Therapeutics Inc., Eidos Therapeutics Inc, Acrotech Biopharma Inc, Spectrum Pharmaceuticals Inc., Neurimmune AG, BELLUS Health Inc, Corino Therapeutics Inc., Celgene Corp, SOM Innovation Biotech S.A
North America was the largest region in the transthyretin amyloidosis treatment market in 2023. The regions covered in the transthyretin amyloidosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the transthyretin amyloidosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The transthyretin amyloidosis treatment market consists of revenues earned by entities by providing biopsy, echocardiography, genetic testing, and imaging studies. The market value includes the value of related goods sold by the service provider or included within the service offering. The transthyretin amyloidosis treatment market also includes sales of tolcapone, and diflunisal. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Transthyretin Amyloidosis Treatment Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on transthyretin amyloidosis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for transthyretin amyloidosis treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The transthyretin amyloidosis treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
The impact of higher inflation in many countries and the resulting spike in interest rates.
The continued but declining impact of COVID-19 on supply chains and consumption patterns.